Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2867MR)

This product GTTS-WQ2867MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2867MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15970MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ12059MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ9231MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ996MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ4006MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ2914MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ1158MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ7595MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW